A Phase II Study of Vinorelbine, Mitomycin C and Cisplatin Chemotherapy for Advanced Non-Small Cell Lung Cancer.
- Author:
Mi Ran KWON
1
;
Tae Yeob JEONG
;
Young Jin YUH
;
Sung Rok KIM
Author Information
1. Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. tufmr@hanmail.net
- Publication Type:Original Article
- Keywords:
Carcinoma;
Non-Small-Cell-Lung;
Vinca Alkaloids;
Mitomycin;
Cisplatin
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology;
Cisplatin/*administration & dosage;
Dose-Response Relationship, Drug;
Female;
Human;
Lung Neoplasms/*drug therapy/pathology;
Male;
Middle Aged;
Mitomycin/*administration & dosage;
Treatment Outcome;
Vinblastine/*administration & dosage/*analogs & derivatives
- From:The Korean Journal of Internal Medicine
2002;17(4):240-244
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: This prospective phase II trial was performed to determine the efficacy and toxicity of mitomycin C, vinorelbine and cisplatin combination chemotherapy for patients with previously untreated stage IIIB or IV non-small cell lung cancer (NSCLC). METHODS: Between January 1999 and April 2001, 30 patients with chemotherapy- naive stage IIIB or IV NSCLC were entered into this study. Mitomycin C at a dose of 7 mg/m2, vinorelbine at a dose of 25 mg/m2 and cisplatin at a dose of 75 mg/m2 on day 1 and vinorelbine at a dose of 25 mg/m2 on day 8 were administered. This regimen was repeated every 4 weeks. RESULTS: 29 patients out of 30 patients were assessable. Among the assessable patients, 15 (51.7%) patients had a partial response. The median duration of response and survival was 22 weeks and 39 weeks, respectively. Grade 3 or 4 leukopenia and thrombocytopenia were observed in 28.3% and 4.7% of all the cycles, respectively. Nausea and vomiting of grade 3 occurred only in 2.4% of all the cycles. CONCLUSION: The regimen of mitomycin C, vinorelbine and cisplatin for non-small cell lung cancer is active against advanced NSCLC with tolerable toxicities.
